FibroGen Future Growth
Future criteria checks 0/6
FibroGen's revenue is forecast to decline at 1.4% per annum while its annual earnings are expected to grow at 71.4% per year. EPS is expected to grow by 74.5% per annum.
Key information
71.4%
Earnings growth rate
74.5%
EPS growth rate
| Biotechs earnings growth | 37.0% |
| Revenue growth rate | -1.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 177 | -9 | N/A | N/A | 2 |
| 12/31/2025 | 152 | -44 | N/A | N/A | 2 |
| 12/31/2024 | 173 | -89 | N/A | N/A | 2 |
| 9/30/2024 | 180 | -122 | -126 | -126 | N/A |
| 6/30/2024 | 174 | -168 | -203 | -202 | N/A |
| 3/31/2024 | 167 | -240 | -275 | -273 | N/A |
| 12/31/2023 | 148 | -284 | -318 | -315 | N/A |
| 9/30/2023 | 155 | -294 | -352 | -349 | N/A |
| 6/30/2023 | 131 | -322 | -319 | -317 | N/A |
| 3/31/2023 | 116 | -307 | -242 | -239 | N/A |
| 12/31/2022 | 141 | -294 | -185 | -146 | N/A |
| 9/30/2022 | 123 | -362 | -188 | -148 | N/A |
| 6/30/2022 | 263 | -220 | -118 | -52 | N/A |
| 3/31/2022 | 258 | -281 | -112 | -46 | N/A |
| 12/31/2021 | 235 | -290 | -112 | -82 | N/A |
| 9/30/2021 | 284 | -215 | -66 | -34 | N/A |
| 6/30/2021 | 172 | -231 | -85 | -80 | N/A |
| 3/31/2021 | 190 | -183 | 92 | 96 | N/A |
| 12/31/2020 | 176 | -189 | 78 | 82 | N/A |
| 9/30/2020 | 119 | -229 | 40 | 44 | N/A |
| 6/30/2020 | 108 | -311 | 13 | 18 | N/A |
| 3/31/2020 | 257 | -110 | -166 | -161 | N/A |
| 12/31/2019 | 257 | -77 | -84 | -79 | N/A |
| 9/30/2019 | 357 | 42 | -58 | -51 | N/A |
| 6/30/2019 | 353 | 49 | -22 | -15 | N/A |
| 3/31/2019 | 205 | -90 | -28 | -22 | N/A |
| 12/31/2018 | 213 | -86 | -84 | -76 | N/A |
| 9/30/2018 | 136 | -141 | -68 | -60 | N/A |
| 6/30/2018 | 147 | -123 | N/A | -87 | N/A |
| 3/31/2018 | 133 | -132 | N/A | -71 | N/A |
| 12/31/2017 | 131 | -121 | N/A | -67 | N/A |
| 9/30/2017 | 132 | -121 | N/A | -84 | N/A |
| 6/30/2017 | 122 | -121 | N/A | -67 | N/A |
| 3/31/2017 | 181 | -64 | N/A | -3 | N/A |
| 12/31/2016 | 183 | -58 | N/A | 7 | N/A |
| 9/30/2016 | 172 | -79 | N/A | -14 | N/A |
| 6/30/2016 | 162 | -100 | N/A | -50 | N/A |
| 3/31/2016 | 193 | -67 | N/A | 6 | N/A |
| 12/31/2015 | 181 | -86 | N/A | -19 | N/A |
| 9/30/2015 | 172 | -85 | N/A | -3 | N/A |
| 6/30/2015 | 167 | -79 | N/A | 4 | N/A |
| 3/31/2015 | 136 | -98 | N/A | -4 | N/A |
| 12/31/2014 | 138 | -60 | N/A | 22 | N/A |
| 9/30/2014 | 134 | -24 | N/A | 24 | N/A |
| 6/30/2014 | 191 | 43 | N/A | 128 | N/A |
| 3/31/2014 | 117 | -5 | N/A | 30 | N/A |
| 12/31/2013 | 102 | -15 | N/A | 26 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0IL8 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0IL8 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0IL8 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0IL8's revenue is expected to decline over the next 3 years (-1.4% per year).
High Growth Revenue: 0IL8's revenue is forecast to decline over the next 3 years (-1.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0IL8's Return on Equity is forecast to be high in 3 years time